In line with its oncogenic function, clinical data in The Cancer Genome Atlas (TCGA) indicated that high expression of EZH2 correlates with shorter progression-free (PFI) and disease-free interval (DFI) in PC patients (Fig. 4A and B). Here, EZH2 is linked to pachyonychia congenita.